Background There are mounting calls for robust, critical evaluation of the impact of patient and public involvement (PPI) in health research. However, questions remain about how to assess its impact, and whether it should be assessed at all. The debate has thus far been dominated by professionals.
Introduction
Public involvement is defined by NIHR INVOLVE, the National Institute for Health Research patient and public involvement advisory group, as 'research being carried out with or by members of the public, rather than to, about or for them'. Members of the public include patients, potential patients, carers and people who use health and social care services as well as people from organizations that represent people who use services. 1 For this reason, it is also often referred to as 'patient and public involvement' (PPI). Many different terms are used internationally to describe patients and members of the public involved in research, such as 'lay representative', 'patient partner' and 'public adviser'. In this study, we adopt the term 'PPI contributor' to avoid implying either that the small number of individuals typically involved in research can represent the diversity of perspectives among patients and the public or that the role of PPI contributors can always be described as a partnership. 2 The evidence base for the impact of PPI in health research is weak and patchy, 3-5 and there are concerns about its implementation without a thorough justification and understanding of its impact. Recently, there have been calls to improve this evidence base and develop better methods to capture, assess and report the impact of PPI. [6] [7] [8] [9] [10] Frameworks such as the Public Involvement Impact Assessment Framework (PiiAF) 11 and Guidance for Reporting the Involvement of Patients and the Public (GRIPP) 10 have been developed, and in-depth realist evaluations have begun to shed light on what works, for whom, under what circumstances and why. 12, 13 There is a general consensus that although PPI has intrinsic value, it should be scrutinized and evaluated, [14] [15] [16] [17] although not everyone agrees that its impact should be quantitatively measured. 18 However, the debate has been dominated by professionals, with little input from patients and members of the public. It has been argued that we need open and honest debate about what is meant by the need to assess the impact of PPI, including who benefits from the assessment and why PPI is being done, before we can conclude that assessment is necessary and determine how to do it. 19 This paper contributes a diverse range of patient and public views to the 'impact debate', as well as shedding light on mechanisms of impact that have so far been underexplored. 8 As part of a wider study exploring views and experiences of patient and public involvement across the UK, 20 here we report on PPI contributors' thoughts and perspectives on the impact of PPI on research and its assessment. We define 'impact' as any effect, positive or negative, that PPI contributors have on research processes, outputs and outcomes, including both an individual's impact within a given project, and the impact of PPI more generally on research and research culture. Although not the focus of this study, the impact of PPI on the people involved (PPI contributors and researchers) is another important aspect of impact which merits investigation. 11 We define the 'assessment' of impact as any attempt to judge, either qualitatively or quantitatively, the effect that PPI has on a research project or research more generally.
Because an extensive range of impacts of PPI has already been identified and reported, 3, 4, 12, 13, 21 we only briefly describe the impacts identified by participants in this study, focusing more on the mechanisms and assessment of impact.
Methods
We recruited a maximum variation sample of patients and members of the public from across the UK. Advertisements were sent to universities and clinical research networks and were distributed among the authors' professional networks and at PPI conferences. The participants had been involved in medical, health or health-related research for various lengths of time (see Table 1 the public with PPI experience (including JB) were involved in the study through an advisory group which also included researchers, clinical staff and representatives from PPI organizations. They advised on sampling, recruitment, the interview guide and themes emerging from the analysis. Two of them also participated in the study. Participants took part in one semi-structured narrative interview with AMB or LL, the wider findings of which are available on the health website. 20 Here, we focus specifically on their views about the impact of PPI on research, elicited using a range of prompts (Box 1). The interviews were video or audio-recorded and transcribed verbatim. LL coded the data with NVivo software (QSR International, Melbourne Australia) using a coding framework developed jointly with AMB. Coding was an iterative process; as new codes were added, previous transcripts were re-coded. JCC then reanalysed the coding report on 'value and impact', using a more refined coding framework developed in discussion with AMB and LL. JB contributed to an initial outline of the paper and successive drafts to refine the analysis and content of the paper.
Results

Participants
Thirty-eight participants consented to be interviewed (see Table 1 ). Four participants had progressed from a lay PPI role to a professional research or research support role since becoming involved in research.
Themes
Four broad themes emerged from the analysis and are presented below: (i) the impact(s) of PPI on research; (ii) PPI roles and mechanisms of impact; (iii) the question of whether or not the impact of PPI should be assessed; and (iv) how the impact of PPI should be assessed.
What is the impact of PPI on research? Participants gave many examples of impact or potential impact on research, including shaping initial research questions and ideas, choosing outcome measures that are relevant and meaningful to patients, ensuring the efficient delivery of research, helping to solve ethical dilemmas, improving the way information is communicated to patients, optimizing the recruitment of participants and their experiences of taking part, collecting and analysing research data, and disseminating research findings to patients and the public. Some gave concrete examples of their own impact on such processes: Participants did not frame any of the described impacts on research as negative, including when PPI resulted in research proposals being abandoned: I said, "I'm thinking about the money you're going to be spending on this . . . piece of research." I said, "I think it's a waste of time, I don't think it's going to work the way you want it to pan out". Anyway they stopped it. . . (P22, carer) Importantly, impact did not always mean 'change'; it could mean validating an existing idea:
I think you're often a sounding board for people who've already got ideas about how a piece of research might run. . . but they need someone to say, "Yeah absolutely that really, really is important to us.". Although convinced that PPI benefited research, some participants found it hard to pin down the impact of their own involvement:
I don't actually know what impact I've had on any of it. No, now you come to talk about it, I have absolutely no idea if anything I have ever done -in the last eight years -has been of any value to anyone at all, which is actually quite a sobering thought. (P32, patient) Some participants encouraged other PPI contributors to seek feedback from researchers to increase the value of their contributions. Impact could change over time and be enhanced through ongoing, reciprocal feedback:
As you're leaving the meeting say to the Chair, "Were those contributions helpful to the meeting?" and get them to tell you if they were. And say to him, "Look I'm new to this, give me advice." I found sometimes that some professionals have said to me, "We'd love it if you asked questions around such and such." (P27, patient)
Roles and mechanisms of impact Participants described themselves and their peers as fulfilling a variety of roles in terms of their 'added value'. We grouped these into six broad categories: the expert in lived experience, the creative outsider, the free challenger, the bridger, the motivator and the passive presence (Table 2 ). These are fluid and not mutually exclusive, for example the bridger may connect researchers to the patients they aim to benefit, thus potentially increasing their motivation.
We see these roles as functioning within a team of research professionals and PPI contributors, as participants stressed the importance of teamwork in driving impact:
It's a different perspective. It is not better. It is not inferior. We need the doctor. We need the scientist. We need the neurologist. We need the PPI. We need a team. And it's a team effort that will eventually yield the results. (P03, carer)
Should the impact of PPI be assessed? Participants were generally in favour of assessing the impact of PPI, to improve the way it is done, to convince sceptical researchers of its benefits or to reduce tokenistic PPI, to justify the cost of PPI and to increase funding for PPI:
. . .this is a big investment that we are making, and so we ought to be contributing something. It's not just about having quite a nice time. (P02, carer) . . .you need to measure things because of the old adage that what gets measured gets done. And if you don't measure things in some way or other then you have no idea whether you're doing well or doing badly. (P09, carer) And that's the other thing about impact, you need to demonstrate it, not just to funders, you need to demonstrate it to other patients so they will get involved and think, 'Yeah I could do this.' (P40, patient) Some participants emphasized the need for individual feedback regarding their own impact, as this would improve their contributions and increase their motivation to stay involved: However, there was a widespread acknowledgement that assessing the impact of PPI is challenging, particularly when PPI is a genuinely collaborative venture. Participant 19 (a patient), for example, described themselves as 'just a little cog' contributing to 'moving in the right direction'. Participant 33 (a patient) felt it was 'more difficult to see a direct result of what you've done the more sophisticated you get with your PPI activity'.
None of the participants appeared to be unequivocally opposed to assessing the impact of PPI. However, some were concerned about assessing impact too simplistically:
. . .if, for instance, you're holding workshops where people are talking with each other, including researchers and, and service users, it's quite difficult to then pull apart whose contribution made which difference. So those things make it quite complicated. So I think simplistic tools for measuring impact can be quite damaging, because they're not likely to notice it. (P02, carer)
Participant 41 (a patient) also questioned the singling out of PPI members rather than others on the research team: 'What about the other people whose expertise you're asking? Are you going to measure the impact the statistician had when you asked him or her to help. . .?'
How should the impact of PPI be assessed? Participants suggested several 'impacts' which could be quantitatively measured: success in gaining research funding, research ethics committee approval and participant recruitment rates. One participant proposed that increased demand for PPI in research was itself evidence of its positive impact:
. . .the biggest indication of our value is that we can't keep up with requests for input. And it's from people that are really good researchers, very well-known, but also from some of the young researchers who've heard about us and actually have come usually via our website and asked for input. . . So the proof of the pudding's in the eating and the number of people that. . .want to buy it. (P31, patient) However, participants varied in their attitudes towards quantitative measurement of impact. Randomized controlled trials were viewed as the most convincing type of evidence, but not necessarily appropriate for assessing PPI impact:
So I think some of the difficulty of that sort of question is, well, what do we mean by evidence? What do we mean by impact? Who is it we're trying to convince by this evidence? Because actually. . . if you're trying to convince somebody who only believes in randomised controlled trials then actually we're never going to probably get evidence. Whereas if you're going to get evidence for people who. . . will consider a broader range of research methods Some participants spoke of the need to move beyond 'anecdotal' evidence of impact, although not everyone agreed that 'anecdotal' evidence was a bad thing:
. . .There's currently a bid out to measure the impact of PPI [. . .] to find tools that measure the impact. . . Because the only way to get it more embedded is to actually be able to point to something that shows -because at the moment it's dismissed as anecdotal evidence and I don't know why anecdotal evidence doesn't count. (P36, patient)
Although relatively tangible impacts were suggested for assessment, many participants proposed that the ultimate aim of PPI was to benefit patients through improved research:
It's no good just going down some wonderfully enthusiastic path as a researcher which may or may not have an impact on the real world. Far better to say, well I would find it more satisfying to be able to say at the end of it, "This research had an impact on hospital practice or what GPs do." To me that is such a valuable output from research that it's well worth taking a little time at the start to get lay input. (P39, patient)
There was some discussion about who should be involved in assessing impact. Some PPI contributors suggested they could keep a record of their own impact, and some said it was important to ask researchers:
You're going to have to ask investigators, particularly chief investigators, principal investigators, the ones who actually put studies together in detail, what their perception of the value is and hopefully they will do more than give the nominally appropriate answer. (P26, patient)
Discussion
Main findings
Participants in this study overwhelmingly expressed the view that PPI has or should have a beneficial impact on health research, describing various positive impacts and potential impacts on research processes which mirror those identified in systematic reviews. 3, 4 This is consistent with the finding of a recent UK consensus study that the majority of public participants felt that PPI leads to research of greater quality and relevance -a view only shared by a minority of academics. 16 In keeping with a qualitative study of PPI in clinical trials, 2 none of the participants reported negative impacts of PPI on research, although some expressed uncertainty about the impact of their own involvement. In our study, this seemed to be in part because of a lack of individual feedback on impact within specific research projects. Such individual feedback was seen as an important driver of impact improvement and motivation to stay involved in research.
Participants described various impactful roles, which we have referred to as the 'expert in lived experience', the 'creative outsider', the 'free challenger', the 'bridger', the 'motivator' and the 'passive presence'. In practice, these roles may frequently overlap and PPI contributors may embody all of them at different times throughout the life of a research project. We hope that this suggested typology helps towards better understanding some of the mechanisms leading to PPI impact, and towards clarifying what types of impact PPI contributors and researchers want PPI to have in research -a crucial step in determining what impacts to assess and how. 15 Determining which of these roles will be prioritized at the outset of research projects could help research teams recruit PPI contributors with the experience, attributes or skills required to fulfil these roles, and could help to clarify goals at an early stage. This may in turn help to increase the perceived value and impact of PPI, as there appears to be a link between chief investigators Participants generally supported the idea of PPI impact assessment, although some questioned whether or not it was possible to do well, given the complex nature of PPI. It was pointed out that the more PPI resembles a partnership, with PPI contributors being part of a team alongside researchers and other professionals, the more difficult it is to isolate the impact of the PPI. This is an important consideration given the indication that a 'fully intertwined' partnership approach leads to greater positive impact. 13 There was some concern about the dangers of oversimplifying the assessment of PPI impact and producing distorted results. These views reflect those of many academic and nonacademic stakeholders who took part in a consensus study about PPI evaluation: 89% expressed the view that PPI impact assessment was very or fairly important, although many acknowledged that such assessment was methodologically challenging. 16 The participants in our study expressed a range of different views about what impacts should be assessed, by whom and how. Given that many of the people we interviewed were involved in quantitative clinical studies, it is perhaps not surprising that there was general acceptance of a biomedical hierarchy of evidence (with randomized controlled trials at the top) and acceptance of a discourse about the need to demonstrate effectiveness in fairly narrow utilitarian terms. Yet people we interviewed also expressed reservations about applying this paradigm to PPI -a complex social process -and its possible unintended consequences.
Strengths and limitations
To our knowledge, this is the first in-depth, UKwide exploration of PPI contributors' views on PPI impact assessment in health research. We hope the findings will be considered alongside the predominantly professional views in current literature. The purposive sampling strategy and one-to-one interviews yielded rich data on a diverse range of views and experiences. In addition, the authors come from different paradigmatic stances and hold differing views on whether and how PPI impact should be assessed. The third author is a PPI contributor herself and was involved in designing the study and interpreting data.
Our study has several limitations. First, the interviews required participants to recall past experiences of PPI, which for some participants stretched back over many years. It may be that in some cases a lack of information, such as examples of participants' own impact or examples of negative impact on research, reflects recall difficulties rather than evidence of absence. Second, participants may have felt reluctant to speak critically about an enterprise they have bought into. The interviewers themselves were researchers (albeit non-clinical), and this may have influenced the way participants spoke about PPI impact and its assessment, for example, softening or omitting disagreement with prevailing academic views (such as the discourse of evidence-based practice and the hierarchy of types of evidence). There remains ample evidence that PPI often takes place in a context of unequal power relations. As Gibson, LewandoHundt and Blaxter argue, in some circumstances PPI 'offers relatively limited opportunities to influence decision making or alter agendas', and can take the form of a 'weak public, lacking in general participatory parity and therefore unable to challenge the boundaries and discourse [of the boards]'. 22 Although their study focused on PPI in service networks rather than research, their conclusion is strongly resonant. Finally, the interview guide covered many different topics, of which PPI impact was only one and probing on this specific topic was therefore limited. In retrospect, specific probing about the potential negative impacts of PPI may have yielded useful findings to complement the positive accounts of PPI impact elicited.
Implications
We believe that there are several important implications of our findings. First, PPI Assessing the impact of PPI in isolation may be perceived as discriminatory, 16 therefore, we would encourage researchers to discuss with their PPI contributors whether such an approach would be helpful, and if so, how it should be done.
